Tradestie Institutional Equity Comparison Engine · Market Close Jul 31, 2026

KVAC vs PSTV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PSTV Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–5 Matrix Metrics)

PSTV Overall Winner 6-Pillar Tally: KVAC 2 – 2 PSTV (2 Tie) Matrix Metrics: KVAC 5 – 5 PSTV

As of Jul 31, 2026, PLUS THERAPEUTICS, Inc. (PSTV) is the stronger overall head-to-head candidate over Keen Vision Acquisition Corporation (KVAC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). KVAC carries a Unified Composite Score of 58.0/100 (HOLD) at $11.51 (N/M Forward P/E, 0.0% operating margin), whereas PSTV carries 59.8/100 (HOLD) at $3.87 (1.0x Forward P/E, -692.5% operating margin).

  • Technical & Structure Timing Caution: KVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile PSTV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KVAC vs PSTV
KVAC US Equity
Keen Vision Acquisition Corporation
Blank Checks
$11.51
-13.13% 1D
Market Cap $73.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.17β · 76% Vol
Unified Composite Score
58.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
PSTV NASDAQ Head-to-Head Winner
PLUS THERAPEUTICS, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$3.87
+6.03% 1D
Market Cap $25.1M
TTM Revenue $5.2M
Forward P/E 1.0x
Beta / 30D Vol 2.04β · 50% Vol
Unified Composite Score
59.8 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 43
RSI-14: 43.3 · SMA20: $3.89 · SMA50: $4.66

6-Pillar Scorecard Institutional Category Breakdown (KVAC 2 – 2 PSTV)

Columns: Metric · KVAC · PSTV
1. Valuation Multiples PSTV
Forward P/E N/M 1.0x
Trailing P/E 88.3x 0.2x
PEG Ratio N/M 2.45x
EV / Revenue N/M 4.4x
2. Growth & Scale KVAC
Revenue Growth (YoY) +0.0% -2.9%
Earnings Growth (YoY) -76.9% +0.0%
TTM Revenue (USD) N/A $5.2M
Market Cap $73.0M $25.1M
3. Profitability & Quality KVAC
Gross Margin N/A -83.1%
Operating Margin 0.0% -692.5%
Net Profit Margin 0.0% -230.2%
Return on Equity (ROE) 0.0% -522.5%
4. Balance Sheet & Cash Flow PSTV
Cash Generation (TTM) -$429,086 -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.6M Net Debt (0.48x D/E) $2.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Shell Companies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KVAC (5) vs PSTV (5)
Institutional Metric KVAC PSTV Criterion Row Edge
Market Capitalization
Scale
$73.0M $25.1M Larger Scale KVAC
Trailing P/E Ratio
Valuation
88.3x 0.2x Lower Multiple PSTV
Forward P/E Ratio
Valuation
N/M 1.0x Lower Multiple PSTV
Revenue Growth (YoY)
Growth
+0.0% -2.9% Higher Growth KVAC
Operating Margin (TTM)
Profitability
0.0% -692.5% Higher Margin KVAC
Net Profit Margin
Profitability
0.0% -230.2% Higher Margin KVAC
Return on Equity (ROE)
Capital Efficiency
0.0% -522.5% Higher ROE KVAC
52-Week Range Position
Momentum
0% ($12–$19) 48% ($0–$8) Stronger Trend PSTV
Beta / 30D Volatility
Risk Regime
-0.17β · 76% Vol 2.04β · 50% Vol Lower Realized Risk PSTV
Unified Institutional Score
Composite Signal
58.0 / 100 (HOLD) 59.8 / 100 (HOLD) Higher Composite PSTV
Trailing 12M Revenue (USD)
Operating Scale
N/A $5.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -83.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.45x PEG · 4.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$429,086 ($1.6M Net Debt (0.48x D/E)) -$22M ($2.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KVAC +34.94 pp
KVAC: -6.42% · PSTV: -41.36%
3M Horizon PSTV +657.46 pp
KVAC: -2.04% · PSTV: +655.42%
6M Horizon PSTV +591.88 pp
KVAC: -1.79% · PSTV: +590.09%
1Y Horizon PSTV +591.88 pp
KVAC: -1.79% · PSTV: +590.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KVAC vs PSTV. Trailing 12-month operating profitability (KVAC 0.0% vs PSTV -692.5%) and valuation multiples (KVAC N/M vs PSTV 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

KVAC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
PSTV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.2M
Gross Margin-83.1%
Op. Margin-692.5%
ROE / Fwd P/E-522.5% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KVAC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KVAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PSTV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PSTV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KVAC Moat Profile Cyclical / Execution-Driven Positioning
Shell Companies Operator
Competes within the Shell Companies value chain with $73.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PSTV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $25.1M market capitalization and -692.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KVAC vs PSTV Key Questions & Quantitative Answers

As of Jul 31, 2026, PLUS THERAPEUTICS, Inc. (PSTV) is the stronger overall head-to-head candidate over Keen Vision Acquisition Corporation (KVAC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). KVAC carries a Unified Composite Score of 58.0/100 (HOLD) at $11.51 (N/M Forward P/E, 0.0% operating margin), whereas PSTV carries 59.8/100 (HOLD) at $3.87 (1.0x Forward P/E, -692.5% operating margin). Technical & Structure Timing Caution: KVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile PSTV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KVAC leads the Growth & Scale pillar: KVAC posts +0.0% YoY revenue growth and -76.9% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PSTV at -2.9% YoY revenue growth and +0.0% YoY earnings growth on $5.2M TTM revenue (-83.1% gross margin, -692.5% operating margin). On trailing 12-month operating scale, KVAC generates N/A in USD-normalized revenue versus $5.2M for PSTV. In operating R&D and SG&A reinvestment, KVAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PSTV.

PSTV screens cheaper on headline valuation multiples. KVAC trades at N/M Forward P/E, 88.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PSTV trades at 1.0x Forward P/E, 0.2x Trailing P/E, 2.45x PEG, and 4.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KVAC (0.0% ROE) versus PSTV (-522.5% ROE) capital efficiency.

In options market volatility and institutional positioning, KVAC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.17β · 76% Vol realized risk). By comparison, PSTV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.04β · 50% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jul 31, 2026. For educational research only; not investment advice.